Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

tafasitamab

(TA-fuh-SIH-tuh-mab)
A drug used with lenalidomide to treat adults with certain types of diffuse large B-cell lymphoma that relapsed (came back) or did not get better after treatment with other anticancer therapy. It is used in patients who cannot be treated with an autologous stem cell transplant. It is also being studied in the treatment of other types of cancer. Tafasitamab binds to a protein called CD19, which is found on most B cells (a type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. Tafasitamab is a type of monoclonal antibody. Also called Monjuvi.
More Information
Search NCI's Dictionary of Cancer Terms